Olpress 20 Tablet contains Olmesartan Medoxomil 20 mg, an angiotensin II receptor blocker (ARB) used primarily for the management of hypertension. By selectively inhibiting the binding of angiotensin II to the AT1 receptor, Olmesartan Medoxomil promotes vasodilation, thereby reducing peripheral vascular resistance and lowering blood pressure. This mechanism helps prevent complications associated with hypertension, such as stroke, myocardial infarction, and renal impairment. Olpress 20 is indicated for adults with essential hypertension and may be used as monotherapy or in combination with other antihypertensive agents to achieve optimal blood pressure control. The tablet is typically administered once daily, with or without food, and dosage adjustments should be individualized based on patient response and tolerability. Common adverse effects include dizziness, headache, and fatigue, while serious side effects are rare but may involve hyperkalemia or renal function alterations. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated during pregnancy due to potential fetal toxicity. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during treatment. Olpress 20 offers an effective therapeutic option for long-term hypertension management, contributing to cardiovascular risk reduction.